Treatment Details – 10.5 months

Survival: 10.5 months
  
Toxicity Grade:3
  
Treatments: Biologic therapy
Chemotherapy
  
Drugs: Mitozytrex
Platinol
Country:United Kingdom
  
City/State/Province:Sutton
  
Hospital:The Royal Marsden Hospital
  
Journal:Link
  
Date: 2/2002

Description:
Patients: This Phase I study involved 13 patients with malignant mesothelioma.

Treatment: The treatment consisted of a suspension of heat-killed Mycobacterium vaccae (SRL172), a fast growing avirulent mycobacterium, that may have non-specific immunomodulating properties in combination with standard chemotherapy (mitomycin-C (mitozytrex), vinblastine (velban) and cisplatin (platinol)).

Toxicity: Grade 1-3 toxicities included infection, emesis, mucositis, diarrhea, constipation, alopecia, neuropathy, fatigue, and hematological.

Results: The median overall survival was 10.5 months.

Support: This study was supported by a research grant from SR Pharma. SR Pharma markets SRL172.

Correspondence: MER O’Brien, MD

Get your free copy of
“Surviving Mesothelioma” Today!